Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5 Carcinoma, Non-Small-Cell Lung 3 Prostatic Neoplasms 2 Polycystic Ovary Syndrome 2 Leukoplakia, Oral 2 Thyroid Cancers That Contain the PAX8-PPARgamma Fusion Gene 1 Skin Neoplasms 1 Pancreatic Neoplasms 1 Lung Neoplasms 1 Liposarcoma, Myxoid 1 Liposarcoma 1 Leukemia, Myeloid, Chronic-Phase 1 Leukemia, Myeloid, Acute 1 Insulin Resistance 1 Head and Neck Neoplasms 1 Carotid Intimal Medial Thickness 1 1 Carcinoma, Squamous Cell 1 Breast Neoplasms 1

Interventions

Trabectedin 3 Radiation Dose Hypofractionation 3 Cyclophosphamide 3 fludarabine 2 ribociclib 1 pembrolizumab 1 interferon gamma-1b 1 cytochrome C synthetase 1 brostallicin 1 atezolizumab 1 Sirolimus 1 Pioglitazone 1 Interferon-gamma 1 Diathermy 1 Dexamethasone 1 Biopsy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Liposarcoma, Myxoid × Pioglitazone × Clear all

NCT04794127 2026-02-18

TRABEPIO

Mario Negri Institute for Pharmacological Research

Phase 2 Completed

Liposarcoma, Liposarcoma, Myxoid

Data powered by HemOnc (CC BY 4.0) Colophon ⚡